Use to confirm pathogenic and pseudodeficiency HEXA gene variants in individuals with abnormal levels of HEX A enzyme. For initial testing of Tay-Sachs disease, refer to Hexosaminidase A percent and Total Hexosaminidase in Leukocytes (2008125).
Polymerase Chain Reaction/Sequencing/Gel Electrophoresis
New York DOH Approval Status
Lavender (EDTA), pink (K2EDTA), or yellow (ACD Solution A or B).
Transport 3 mL whole blood. (Min: 1 mL)
Ambient: 72 hours; Refrigerated: 1 week; Frozen: Unacceptable
Background for Tay-Sachs Disease (HEXA) Sequencing and 7.6kb Deletion:
Characteristics: Hexosaminidase A (HEX A) enzyme deficiency is characterized by neuronal deterioration resulting in intellectual disability and motor retardation. Clinical severity is variable. Onset by six months of age with rapid progression is seen with Tay-Sachs disease (acute infantile form), while juvenile and adult-onset forms manifest a less severe course. HEX A deficiency results in the accumulation and lysosomal storage of GM2 (ganglioside).
Incidence: Varies by ethnicity. 1 in 3,000 for Ashkenazi Jewish and French Canadians; other high-risk populations include Louisiana Cajuns and Old Order Amish. 1 in 300,000 for the general population.
Inheritance: Autosomal recessive.
Cause: Two pathogenic germline HEXA gene mutations on opposite chromosomes.
Clinical Sensitivity: 99 percent.
Methodology: Bidirectional sequencing of all coding regions and intron/exon boundaries of the HEXA gene. Agarose gel electrophoresis to assess for the 7.6kb deletion.
Analytical Sensitivity and Specificity: 99 percent.
Limitations: Diagnostic errors can occur due to rare sequence variations. Regulatory region mutations and deep intronic mutations will not be detected. Large deletions/duplications in HEXA, other than the 7.6kb deletion, will not be detected.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Counseling and informed consent are recommended for genetic testing. Consent forms are available online.
Laboratory Developed Test (LDT)
|Component Test Code*||Component Chart Name||LOINC|
|2009299||Tay-Sachs Disease (HEXA) Seq, Specimen||31208-2|
|2009300||Tay-Sachs Disease (HEXA) Seq, Interp||35473-8|